Post-Transplantation Lymphoproliferative Disorder and OKT3

Abstract

Swinnen et al. (Dec. 20 issue) reported an 11.4 percent incidence of post-transplantation lymphoproliferative disorder associated with the administration of OKT3 in heart-transplant recipients.¹ This experience is not consistent with that at the Minneapolis Heart Institute, where a prophylactic OKT3 regimen has been used in high-risk heart-transplant recipients for 45 months.²